Lucid Diagnostics Secures Important Contract with VA
Lucid Diagnostics Inc. (NASDAQ: LUCD) has made a significant stride in cancer prevention by securing a contract with the U.S. Department of Veterans Affairs (VA) for its EsoGuard® esophageal DNA test. This contract aims to expand access to esophageal precancer testing across the VA's extensive healthcare system, which caters to more than nine million veterans every year.
Benefits of the Contract
This contract, provided under the VA's Federal Supply Schedule, offers pre-negotiated pricing for EsoGuard that aligns with Medicare's payment rate, duly established by the Centers for Medicare & Medicaid Services (CMS). This arrangement allows the numerous VA hospitals and healthcare facilities to procure EsoGuard efficiently and effectively through a unified national framework.
Commitment to Veteran Health
Shaun O'Neil, the President and Chief Operating Officer of Lucid Diagnostics, expressed pride in this collaboration with the VA. He highlighted that the VA's extensive operational scale signifies the strength of the clinical evidence backing the EsoGuard test. Lucid is enthusiastic about this partnership and anticipates that working with the VA and other health systems across the nation will aid in incorporating EsoGuard into standard clinical practices.
About EsoGuard® and Its Importance
EsoGuard® is designed for patients suffering from gastroesophageal reflux disease (GERD), often referred to as chronic heartburn, a condition that could lead to serious health issues such as esophageal precancer and cancer. This innovative test is non-invasive, and it's conducted through a simple office procedure, making cancer prevention more accessible to many.
Integrating New Technologies
In conjunction with the EsoGuard® test, Lucid Diagnostics also provides the EsoCheck® Esophageal Cell Collection Device. This combination represents the pioneers of commercially available tools focused on the early detection of esophageal cancer in at-risk patients, potentially saving lives through timely interventions.
The Future of Cancer Prevention
The proactive measures that Lucid Diagnostics is taking are crucial in the battle against cancer, particularly for individuals susceptible to the development of pre-cancerous conditions. The partnership with the VA signifies a vital opportunity to reach a broader population of veterans, ensuring they receive the preventive care necessary to combat potential health risks.
Learn More About Lucid Diagnostics
Lucid Diagnostics remains committed to advancing cancer detection technologies. Their unwavering focus is on developing innovative health solutions that significantly impact the lives of patients. Further information about their services and innovative products can be found on their official website.
Frequently Asked Questions
What is the purpose of the EsoGuard® test?
EseGuard® is designed to detect precancerous conditions in patients at risk, enhancing early diagnosis and prevention of esophageal cancer.
How does the contract with the VA benefit veterans?
The contract provides veterans easier access to EsoGuard testing, improving their chances of early detection and better outcomes through preventive healthcare.
What is the significance of the VA Federal Supply Schedule?
The VA Federal Supply Schedule allows for streamlined procurement and pricing consistency across VA healthcare facilities, making it easier for them to offer EsoGuard.
How does EsoCheck® assist in cancer detection?
EsoCheck® is used to collect esophageal cells easily in a non-invasive manner, complementing the EsoGuard® test for better diagnostic accuracy.
Where can I find more information about Lucid Diagnostics?
More details can be accessed on their official website, which details their offerings and commitment to cancer prevention.
